Nu Skin Enterprises Inc (NUS)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NYSE
Market Cap: $196.17M
Last updated: Nov 17, 2026 at 11:06 AM ET
Nu Skin Enterprises Inc (NUS) Earnings: Report Dates and Results
Nu Skin Enterprises (NUS) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Nu Skin Enterprises reported EPS of $0.10, below the $0.21 estimate. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NUS has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 6.9% below the $0.29 reported for the quarter ended Dec 31, 2025.
NUS Earnings Call
The latest NUS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, NUS beat 26, missed 9 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $311.01M, down 14.6% from $364.21M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.10 | $0.21 | $0.21 - $0.21 | -52.38% | Miss | -70.6% | 1 | 0 up, 1 down | Nov 5, 2026 | $311.01M |
| Jun 30, 2026 | $0.20 | $0.20 | $0.20 - $0.20 | 0.00% | In line | -53.5% | 1 | 1 up, 0 down | Aug 9, 2026 | $320.11M |
| Mar 31, 2026 | $0.14 | $0.15 | $0.15 - $0.15 | -6.67% | Miss | -93.4% | 1 | 0 up, 1 down | May 7, 2026 | $320.61M |
| Dec 31, 2025 | $0.29 | $0.30 | $0.30 - $0.30 | -3.33% | Miss | -23.7% | 1 | 0 up, 1 down | Feb 12, 2026 | $370.32M |
| Sep 30, 2025 | $0.34 | $0.30 | $0.30 - $0.30 | +13.33% | Beat | +100.0% | 1 | 0 up, 1 down | Nov 6, 2025 | $364.21M |
| Jun 30, 2025 | $0.43 | $0.25 | N/A | +72.00% | Beat | +104.8% | 1 | 0 up, 1 down | Aug 7, 2025 | $386.14M |
| Mar 31, 2025 | $2.14 | $0.15 | N/A | N/A | N/A | +2273.7% | 1 | 0 up, 1 down | May 8, 2025 | $364.49M |
| Dec 31, 2024 | $0.38 | $0.22 | $0.20 - $0.23 | +72.73% | Beat | +2.7% | 3 | 1 up, 1 down | Feb 13, 2025 | $445.55M |
| Sep 30, 2024 | $0.17 | $0.20 | $0.19 - $0.21 | -15.00% | Miss | -69.6% | 3 | 0 up, 0 down | Nov 7, 2024 | $430.14M |
| Jun 30, 2024 | $0.21 | $0.17 | $0.15 - $0.20 | +23.53% | Beat | -61.1% | 3 | 0 up, 0 down | Aug 8, 2024 | $439.08M |
| Mar 31, 2024 | $0.09 | $0.05 | $0.05 - $0.05 | +80.00% | Beat | -75.7% | 3 | 0 up, 0 down | May 8, 2024 | $417.31M |
| Dec 31, 2023 | $0.37 | $0.28 | $0.24 - $0.33 | +32.14% | Beat | -58.4% | 4 | 0 up, 0 down | Feb 14, 2024 | $488.64M |
| Sep 30, 2023 | $0.56 | $0.62 | $0.57 - $0.69 | -9.68% | Miss | +19.1% | 4 | 0 up, 1 down | Nov 1, 2023 | $498.77M |
| Jun 30, 2023 | $0.54 | $0.53 | $0.49 - $0.58 | +1.89% | Beat | -29.9% | 4 | 0 up, 0 down | Aug 1, 2023 | $500.26M |
| Mar 31, 2023 | $0.37 | $0.33 | $0.29 - $0.35 | +12.12% | Beat | -51.3% | 4 | 0 up, 0 down | May 3, 2023 | $481.46M |
| Dec 31, 2022 | $0.89 | $0.54 | $0.50 - $0.59 | +64.81% | Beat | +1.1% | 4 | 1 up, 0 down | Feb 15, 2023 | $522.34M |
| Sep 30, 2022 | $0.47 | $0.78 | $0.76 - $0.80 | -39.74% | Miss | -51.5% | 4 | 0 up, 0 down | Nov 2, 2022 | $537.80M |
| Jun 30, 2022 | $0.77 | $0.75 | $0.65 - $0.85 | +2.67% | Beat | -33.0% | 5 | 1 up, 1 down | Aug 4, 2022 | $560.62M |
| Mar 31, 2022 | $0.76 | $0.72 | $0.70 - $0.75 | +5.56% | Beat | -16.5% | 5 | 0 up, 0 down | May 4, 2022 | $604.90M |
| Dec 31, 2021 | $0.88 | $0.95 | $0.92 - $1.00 | -7.37% | Miss | -37.1% | 5 | N/A | Feb 16, 2022 | $673.44M |
| Sep 30, 2021 | $0.97 | $0.86 | N/A | +12.79% | Beat | -10.2% | 5 | N/A | Nov 3, 2021 | $641.15M |
| Jun 30, 2021 | $1.15 | $1.06 | $1.00 - $1.07 | +8.49% | Beat | +42.0% | 6 | N/A | Aug 4, 2021 | $704.05M |
| Mar 31, 2021 | $0.91 | $0.72 | $0.69 - $0.76 | +26.39% | Beat | +152.8% | 6 | N/A | May 5, 2021 | $677.03M |
| Dec 31, 2020 | $1.40 | $1.18 | $1.15 - $1.24 | +18.64% | Beat | +94.4% | 7 | N/A | Feb 10, 2021 | $748.19M |
| Sep 30, 2020 | $1.08 | $0.96 | $0.83 - $1.05 | +12.50% | Beat | +36.7% | 7 | N/A | Nov 4, 2020 | $703.35M |
| Jun 30, 2020 | $0.81 | $0.65 | $0.47 - $0.74 | +24.62% | Beat | -2.4% | 7 | N/A | Aug 5, 2020 | $612.37M |
| Mar 31, 2020 | $0.36 | $0.25 | $0.18 - $0.33 | +44.00% | Beat | -53.2% | 7 | N/A | May 6, 2020 | $518.03M |
| Dec 31, 2019 | $0.72 | $0.74 | N/A | -2.70% | Miss | -31.4% | 7 | N/A | Feb 12, 2020 | $583.36M |
| Sep 30, 2019 | $0.79 | $0.76 | $0.74 - $0.79 | +3.95% | Beat | -24.8% | 7 | N/A | Nov 5, 2019 | $589.93M |
| Jun 30, 2019 | $0.83 | $0.83 | $0.82 - $0.83 | 0.00% | In line | -23.1% | 8 | N/A | Aug 6, 2019 | $623.50M |
| Mar 31, 2019 | $0.77 | $0.72 | $0.65 - $0.75 | +6.94% | Beat | -2.5% | 8 | N/A | Apr 30, 2019 | $623.62M |
| Dec 31, 2018 | $1.05 | $1.05 | $1.01 - $1.10 | 0.00% | In line | -12.5% | 8 | N/A | Feb 13, 2019 | $683.29M |
| Sep 30, 2018 | $1.05 | $0.98 | N/A | +7.14% | Beat | +38.2% | N/A | N/A | Nov 7, 2018 | $675.31M |
| Jun 30, 2018 | $1.08 | $0.93 | $0.85 - $0.96 | +16.13% | Beat | +40.3% | 8 | N/A | Aug 2, 2018 | $704.19M |
| Mar 31, 2018 | $0.79 | $0.70 | $0.59 - $0.81 | +12.86% | Beat | +54.9% | 6 | N/A | Apr 26, 2018 | $616.22M |
| Dec 31, 2017 | $1.20 | $1.19 | $1.10 - $1.22 | +0.84% | Beat | +51.9% | 7 | N/A | Feb 15, 2018 | $666.20M |
| Sep 30, 2017 | $0.76 | $0.76 | $0.75 - $0.78 | 0.00% | In line | -14.6% | 6 | N/A | Nov 1, 2017 | $563.70M |
| Jun 30, 2017 | $0.77 | $0.69 | $0.66 - $0.72 | +11.59% | Beat | -2.5% | 7 | N/A | Aug 2, 2017 | $550.10M |
| Mar 31, 2017 | $0.51 | $0.50 | N/A | +2.00% | Beat | +21.4% | N/A | N/A | May 3, 2017 | $499.10M |
| Dec 31, 2016 | $0.79 | $0.80 | N/A | -1.25% | Miss | +27.4% | N/A | N/A | Feb 16, 2017 | $531.33M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.20, up 276.0% from the year before. It was $2.89 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.20 | +276.0% |
| Dec 31, 2024 | $0.85 | -53.8% |
| Dec 31, 2023 | $1.84 | -36.3% |
| Dec 31, 2022 | $2.89 | -26.1% |
| Dec 31, 2021 | $3.91 | +7.1% |
| Dec 31, 2020 | $3.65 | +17.4% |
| Dec 31, 2019 | $3.11 | -21.7% |
| Dec 31, 2018 | $3.97 | +22.5% |
| Dec 31, 2017 | $3.24 | +12.1% |
| Dec 31, 2016 | $2.89 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,000 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,010 | 5 | |
| 2026Q2 | Jun 30, 2026 | 3,669 | 5 | |
| 2026Q1 | Mar 31, 2026 | 4,265 | 5 | |
| 2025Q4 | Dec 31, 2025 | 4,586 | 5 | |
| 2025Q3 | Sep 30, 2025 | 4,015 | 5 | |
| 2025Q2 | Jun 30, 2025 | 3,622 | 5 | |
| 2025Q1 | Mar 31, 2025 | 2,842 | 4 | |
| 2024Q4 | Dec 31, 2024 | 4,002 | 6 |
2026Q3 Earnings Call
Opening remarks
B.G. Hunt VP of Investor Relations Thanks, Janelle, and good afternoon, everyone. I am joined by Ryan Napierski, President and CEO, and by our interim CFO, Chelsea Lantz. Today, we will be sharing Nu Skin's Q3 2026 results and providing guidance for the remainder of the year. Before I turn the time over to Ryan, let me point out that on today's call, comments will be made that include forward-looking statements. These statements involve important risks and uncertainties, and actual results may differ materially from those discussed or anticipated. Please refer to today's earnings release and our SEC filings for a complete discussion of these risks. Also, during the call, certain financial numbers may be discussed that differ from comparable numbers obtained in our financial statements. We believe these non-GAAP numbers assist in comparing period-to-period results in a more consistent manner. Please refer to our investor website, ir.nuskin.com, for any required reconciliation of these non-GAAP numbers. With that, I would now like to turn the call over to Ryan.
Ryan Napierski President and CEO Thanks, B.G. Good afternoon, everyone, and thanks for joining for our third quarter call. We delivered revenue of $311 million and adjusted EPS of $0.10, both within our guidance range. Our Rhyz manufacturing platform had an exceptional quarter, posting strong year-over-year revenue growth. While our results reflect ongoing pressures in the core business, we remain focused on our strategic priorities that we have outlined over the last year. Our Chief Operating Officer, Chayce Clark, has been leading the team to simplify, focus, and execute upon each of them. These priorities are, number one, advancing our integrated anti-aging platform. Number two, strengthening our channel through improved sales force activation and development. Three, preparing for a formal launch of India early next year. And four, improving our operating model to support greater profitability over time. Let me briefly update you on each of these priorities. First, we continue to make progress in advancing our integrated anti-aging platform, with Prysm iO playing an increasingly important role in our approach to personalized wellness. Prysm is designed to help consumers better understand their nutritional health status and engage more consistently with our wellness product solutions, creating a differentiated experience that connects technology, products, and ongoing customer relationships. Since launching Prysm through the end of Q3, we have now placed approximately 41,000 devices globally and completed 4.5 million scans. During the quarter, we rolled out version 2.0 of the app, which delivers a meaningfully improved user experience powered by our new intelligence AI integration. Since the app update, we have more than doubled our scan-to-purchase conversion rate to 10%, which tells us that consumers are taking action when we get them more engaged with the platform.
Frequently Asked Questions About NUS
When is Nu Skin Enterprises's next earnings date?
Nu Skin Enterprises's next earnings report is expected for Feb 10, 2027.
Did NUS beat earnings estimates last quarter?
No. Nu Skin Enterprises reported EPS of $0.10 for the quarter ended Sep 30, 2026, below the $0.21 estimate by 52.38%.
What EPS do analysts expect from NUS next quarter?
The consensus EPS estimate for Nu Skin Enterprises for the quarter ending Dec 31, 2026 is $0.27 from 2 analysts, with estimates from $0.26 to $0.28.
How often does NUS beat earnings estimates?
Nu Skin Enterprises beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +10.08%.
NUS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors